Navigation path

Left navigation

Additional tools

Other available languages: FR DE

European Commission - Press release

Ebola response: EU scales up aid with planes, material aid and research support

Brussels, 06 November 2014

The European Union and its Member States have now pledged more than €1 billion in response to the Ebola crisis in West Africa. This means the Union has already gone beyond the target set by the European Council on 24 October for €1 billion in assistance to stem the epidemic.

The EU is boosting its investment in Ebola research, sending more material aid and providing new capacity for medical evacuations of international aid workers.

This announcement comes just ahead of the mission of the European Union's Ebola Coordinator and Commissioner for Humanitarian Aid and Crisis Management Christos Stylianides and the Commissioner for Health, Vytenis Andriukaitis to the Ebola-affected countries in West Africa,

The European Commission, together with the European pharmaceutical industry, is launching a €280 million call for proposals to boost research on Ebola. This will help address the current epidemic and manage future outbreaks.

The European Commissioner for Research, Science and Innovation Carlos Moedas said: "The EU is determined to help find a solution to Ebola. We are putting our money where our mouth is and boosting EU research on Ebola with an additional €280 million. With this funding from Horizon 2020 and our industry partners, we are stepping up the development of new vaccines and medications to help save lives around the world".

 The EU is also beginning its biggest single operation of transporting material assistance to the affected countries. A Dutch ship is sailing today from the Netherlands, loaded with ambulances, mobile hospitals, laboratories and other equipment. The cargo has been provided by nine Member States (AT, BE, CZ, FI, HU, NL, RO, SK, UK) and UNICEF. The EU Civil Protection Mechanism is coordinating the operation.

"By pooling our resources, Europe's efforts make a much bigger difference on the ground. At a moment when the availability of medical evacuations is such a crucial factor for encouraging more medical workers to join the Ebola response, I particularly welcome Luxembourg's leadership on this priority with the contribution of specially equipped planes," said Commissioner Stylianides.

Luxembourg has become the first EU Member State to commit aeroplanes for European medical evacuation operations of international humanitarian workers diagnosed with Ebola. The two planes are retrofitted for the purpose with co-funding by the European Commission which will also finance the bulk of the transport costs for evacuations under the EU Civil Protection Mechanism.


The European Union has been active in the response to the Ebola emergency from the start. With today's announcement, more than € 1 billion has been pledged by Member States and the European Commission for this crisis. On 24 October 2014 the European Council appointed Christos Stylianides as the EU Ebola Coordinator.

Mobile laboratories, humanitarian experts, and specialists in dangerous infectious diseases have been deployed to the region. Material assistance: from protective medical equipment through ambulances to field hospitals, has been provided by Member States under the coordination of the European Commission. The Commission is supporting the building and recovery of the health services of the affected countries and is funding research into Ebola vaccines.

The €280 million call for proposals, launched today by the European Commission and the European pharmaceutical industry, is under the Innovative Medicines Initiative (IMI). €140 million will come from Horizon 2020, the EU's framework programme for research and innovation, and €140 million from the pharmaceutical companies which are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The call for proposals will use a new fast-track procedure to get successful projects up and running early next year. The research will involve large-scale clinical trials of new vaccines in the Ebola-affected countries as well as the development of fast diagnostic tests and new approaches to manufacture and distribute vaccines.

For more information

EU websites on Ebola response:

Factsheet on EU response to Ebola:

Factsheet on ERCC

IMI website

Horizon 2020 website


Press contacts

Catherine Ray (+32 2 296 99 21)
Irina Novakova (+ 32 2 295 75 17)
Lucia Caudet (+32 2 295 61 82)
Mirna Bratoz (+32 2 298 72 78)

General public inquiries:

Side Bar